The pro-healing effects of heparan sulfate and growth factors are enhanced by the heparinase enzyme: New association for skin wound healing treatment

Effective treatment strategies for skin wound repair are the focus of numerous studies. New pharmacological approaches appear necessary to guarantee a correct and healthy tissue regeneration. For these reasons, we purposed to investigate the effects of the combination between heparan sulfate and growth factors further adding the heparinase enzyme. Interestingly, for the first time, we have found that this whole association retains a marked pro-healing activity when topically administered to the wound. In detail, this combination significantly enhances the motility and activation of the main cell populations involved in tissue regeneration (keratinocytes, fibroblasts and endothelial cells), compared with single agents administered without heparinase. Notably, using an experimental C57BL/6 mouse model of skin wounding, we observed that the topical treatment of skin lesions with heparan sulfate + growth factors + heparinase promotes the highest closure of wounds compared to each substance mixed with the other ones in all the possible combinations. Eosin/hematoxylin staining of skin biopsies revealed that treatment with the whole combination allows the formation of a well-structured matrix with numerous new vessels. Confocal analyses for vimentin, FAP1α, CK10 and CD31 have highlighted the presence of activated fibroblasts, differentiated keratinocytes and endothelial cells at the closed region of wounds. Our results encourage defining this combined treatment as a new and appealing therapy expedient in skin wound healing, as it is able to activate cell components and promote a dynamic lesions closure.

A multidisciplinary functional proteomics-aided strategy as a tool for the profiling of a novel cytotoxic thiadiazolopyrimidone

In recent years, thiadiazolopyrimidine derivatives have been acknowledged for their striking poly-pharmacological framework, thus representing an interesting scaffold for the development of new therapeutic candidates. This paper examines the synthesis and the interactome characterization of a novel bioactive thiadiazolopyrimidone (compound 1), endowed with cytotoxic activity on HeLa cancer cells. In detail, starting from a small set of synthesized thiadiazolopyrimidones, a multi-disciplinary strategy has been carried out on the most bioactive one to disclose its potential biological targets by functional proteomics, using a label-free mass spectrometry based platform coupling Drug Affinity Responsive Target Stability and targeted Limited Proteolysis-Multiple Reaction Monitoring. The identification of Annexin A6 (ANXA6) as compound 1 most reliable cellular partner paved the way to deepen the protein-ligand interaction through bio-orthogonal approaches and to prove compound 1 action on migration and invasion processes governed by ANXA6 modulation. The identification of compund 1 as the first ANXA6 protein modulator represents a relevant tool to further explore the biological role of ANXA6 in cancer, as well as to develop novel anticancer candidates.

Supercritical Impregnation of Mesoglycan and Lactoferrin on Polyurethane Electrospun Fibers for Wound Healing Applications

Fibrous membranes of thermoplastic polyurethane (TPU) were fabricated through a uni-axial electrospinning process. Fibers were then separately charged with two pharmacological agents, mesoglycan (MSG) and lactoferrin (LF), by supercritical CO₂ impregnation. Scanning Electron Microscopy (SEM) and Energy Dispersive X-ray Spectroscopy (EDS) analysis proved the formation of a micrometric structure with a homogeneous distribution of mesoglycan and lactoferrin. Besides, the degree of retention is calculated in four liquid media with different pHs. At the same time, angle contact analysis proved the formation of a hydrophobic membrane loaded with MSG and a hydrophilic LF-loaded one. The impregnation kinetics demonstrated a maximum loaded amount equal to 0.18 ± 0.20% and 0.07 ± 0.05% for MSG and LT, respectively. In vitro tests were performed using a Franz diffusion cell to simulate the contact with the human skin. The release of MSG reaches a plateau after about 28 h while LF release leveled off after 15 h. The in vitro compatibility of electrospun membranes has been evaluated on HaCaT and BJ cell lines, as human keratinocytes and fibroblasts, respectively. The reported data proved the potential application of fabricated membranes for wound healing.

Targeting USP-7 by a Novel Fluorinated 5-Pyrazolyl-Urea Derivative

The impact of innovative technologies on the target discovery has been employed here to characterize the interactome of STIRUR 41, a promising 3-fluoro-phenyl-5-pyrazolyl-urea derivative endowed with anti-cancer activity, on neuroblastoma-related cells. A drug affinity responsive target stability-based proteomic platform has been optimized to elucidate the molecular mechanism at the basis of STIRUR 41 action, together with immunoblotting analysis and in silico molecular docking. Ubiquitin Specific Protease 7 (USP-7), one of the deubiquitinating enzymes which protect substrate proteins from proteasomal degradation, has been identified as the most affine STIRUR 41 target. As further demonstrated by in vitro and in-cell assays, STIRUR 41 was able to inhibit both the enzymatic activity of USP-7 and its expression levels in neuroblastoma-related cells, thus laying an encouraging base for the blockade of USP-7 downstream signaling.

The Protecting Activity of RIPACUT®: A New Therapeutic Approach Preserving Epithelial Health Based on the Combination of Iceland Lichen Extract, Silver Salt, and Sodium Hyaluronate

Epithelial integrity and function must be maintained in a dynamic healthy equilibrium, keeping unaltered the oxidative and inflammatory conditions and the microbiome of the cutaneous layers. Beside the skin, other mucous membranes can be injured, such as the nasal and anal ones, because of the contact with the external environment. Here, we detected the effects of RIPACUT^®, a combination of Iceland lichen extract, silver salt and sodium hyaluronate that individually act in diverse biological ways. The findings we obtained on keratinocytes, nasal and intestinal epithelial cells reveal that this combination showed a marked antioxidant activity, further assessed by the DPPH assay. Additionally, by analyzing the release of the IL-1β, TNF-α and IL-6 cytokines, we proved the anti-inflammatory effect of RIPACUT^®. In both cases, the main preserving action was due to Iceland lichen. We also observed a notable antimicrobial activity mediated by the silver compound. These data suggest that RIPACUT^® could signify the basis for an attractive pharmacological approach to maintaining healthy epithelial conditions. Interestingly, this may be extended to the nasal and anal areas where it protects against oxidative, inflammatory and infectious insults. Thus, these outcomes encourage the creation of sprays or creams for which sodium hyaluronate can guarantee a surface film-forming effect.

Simvastatin Reduces Doxorubicin-Induced Cardiotoxicity: Effects beyond Its Antioxidant Activity

This study aimed to evaluate if Simvastatin can reduce, and/or prevent, Doxorubicin (Doxo)-induced cardiotoxicity. H9c2 cells were treated with Simvastatin (10 µM) for 4 h and then Doxo (1 µM) was added, and the effects on oxidative stress, calcium homeostasis, and apoptosis were evaluated after 20 h. Furthermore, we evaluated the effects of Simvastatin and Doxo co-treatment on Connexin 43 (Cx43) expression and localization, since this transmembrane protein forming gap junctions is widely involved in cardioprotection. Cytofluorimetric analysis showed that Simvastatin co-treatment significantly reduced Doxo-induced cytosolic and mitochondrial ROS overproduction, apoptosis, and cytochrome c release. Spectrofluorimetric analysis performed by means of Fura2 showed that Simvastatin co-treatment reduced calcium levels stored in mitochondria and restored cytosolic calcium storage. Western blot, immunofluorescence, and cytofluorimetric analyses showed that Simvastatin co-treatment significantly reduced Doxo-induced mitochondrial Cx43 over-expression and significantly increased the membrane levels of Cx43 phosphorylated on Ser368. We hypothesized that the reduced expression of mitochondrial Cx43 could justify the reduced levels of calcium stored in mitochondria and the consequent induction of apoptosis observed in Simvastatin co-treated cells. Moreover, the increased membrane levels of Cx43 phosphorylated on Ser368, which is responsible for the closed conformational state of the gap junction, let us to hypothesize that Simvastatin leads to cell-to-cell communication interruption to block the propagation of Doxo-induced harmful stimuli. Based on these results, we can conclude that Simvastatin could be a good adjuvant in Doxo anticancer therapy. Indeed, we confirmed its antioxidant and antiapoptotic activity, and, above all, we highlighted that Simvastatin interferes with expression and cellular localization of Cx43 that is widely involved in cardioprotection.

A DR/NIR Hybrid Polymeric Tool for Functional Bio-Coatings: Theoretical Study, Cytotoxicity, and Antimicrobial Activity

Among modern biomaterials, hybrid tools containing an organic component and a metal cation are recognized as added value, and, for many advanced biomedical applications, synthetic polymers are used as thin protective/functional coatings for medical or prosthetic devices and implants. These materials require specific non-degradability, biocompatibility, antimicrobial, and antiproliferative properties to address safety aspects concerning their use in medicine. Moreover, bioimaging monitoring of the biomedical device and/or implant through biological tissues is a desirable ability. This article reports a novel hybrid metallopolymer obtained by grafting zinc-coordinated fragments to an organic polymeric matrix. This hybrid polymer, owing to its relevant emission in the deep red to near-infrared (DR/NIR) region, is monitorable; therefore, it represents a potential material for biomedical coating. Furthermore, it shows good biocompatibility and adhesion properties and excellent stability in slightly acidic/basic water solutions. Finally, in contact with the superficial layers of human skin, it shows antimicrobial properties against Staphylococcus aureus bacterial strains.

IFNγ-dependent silencing of TFF1 during Helicobacter pylori infection

Chronic Helicobacter pylori infection is the leading cause of intestinal-type adenocarcinoma, as prolonged Helicobacter colonization triggers chronic active gastritis, which may evolve into adenocarcinoma of the intestinal type. In this environment, cytokines play a significant role in determining the evolution of the infection. In combination with other factors (genetic, environmental and nutritional), the pro-inflammatory response may trigger pro-oncogenic mechanisms that lead to the silencing of tumour-suppressor genes, such as trefoil factor 1 (TFF1). The latter is known to play a protective role by maintaining the gastric mucosa integrity and retaining H. pylori in the mucus layer, preventing the progression of infection and, consequently, the development of gastric cancer (GC). Since TFF1 expression is reduced during chronic Helicobacter infection with a loss of gastric mucosa protection, we investigated the molecular pathways involved in this reduction. Specifically, we evaluated the effect of some pro-inflammatory cytokines on TFF1 regulation in GC and primary gastric cells by RT-qPCR and luciferase reporter assay analyses and the repressor role of the transcription factor C/EBPβ, overexpressed in gastric-intestinal cancer. Our results show that, among several cytokines, IFNγ stimulates C/EBPβ expression, which acts as a negative regulator of TFF1 by binding its promoter at three different sites.

Effects of Hst3p inhibition in Candida albicans: a genome-wide H3K56 acetylation analysis

Candida spp. represent the third most frequent worldwide cause of infection in Intensive Care Units with a mortality rate of almost 40%. The classes of antifungals currently available include azoles, polyenes, echinocandins, pyrimidine derivatives, and allylamines. However, the therapeutical options for the treatment of candidiasis are drastically reduced by the increasing antifungal resistance. The growing need for a more targeted antifungal therapy is limited by the concern of finding molecules that specifically recognize the microbial cell without damaging the host. Epigenetic writers and erasers have emerged as promising targets in different contexts, including the treatment of fungal infections. In C. albicans, Hst3p, a sirtuin that deacetylates H3K56ac, represents an attractive antifungal target as it is essential for the fungus viability and virulence. Although the relevance of such epigenetic regulator is documented for the development of new antifungal therapies, the molecular mechanism behind Hst3p-mediated epigenetic regulation remains unrevealed. Here, we provide the first genome-wide profiling of H3K56ac in C. albicans resulting in H3K56ac enriched regions associated with Candida sp. pathogenicity. Upon Hst3p inhibition, 447 regions gain H3K56ac. Importantly, these genomic areas contain genes encoding for adhesin proteins, degradative enzymes, and white-opaque switching. Moreover, our RNA-seq analysis revealed 1330 upregulated and 1081 downregulated transcripts upon Hst3p inhibition, and among them, we identified 87 genes whose transcriptional increase well correlates with the enrichment of H3K56 acetylation on their promoters, including some well-known regulators of phenotypic switching and virulence. Based on our evidence, Hst3p is an appealing target for the development of new potential antifungal drugs.

Cytotoxic abietane diterpenoids from Salvia leriifolia Benth

The Phytochemical profiling of the root extract of Salvia leriifolia, an endemic plant of Iran, was investigated and 16 abietane diterpenes were isolated, and three were original compounds. 1D and 2D NMR and HRMS performed structural elucidation. The absolute configuration of the previously unreported compounds was determined by circular dichroism (ECD). The cytotoxicity of the isolated compounds was investigated against AGS, MIA PaCa-2, HeLa, and MCF-7 cell lines by the MTT assay. The known diterpene pisiferal possesses high cytotoxicity against all investigated cell lines at a concentration between 9.3 ± 0.6 and 14.38 ± 1.4 μM.

Production of Mesoglycan/PCL Based Composites through Supercritical Impregnation

The development of targeted therapies for wound repair is knowing a growing interest due to the increasing aging of the population and the incidence of chronic pathologies, mainly pressure ulcers. Among molecules recruiting cell populations and promoting the formation of new vital tissue, sodium mesoglycan (MSG) has been proven to be effective in wound healing. In this work, MSG impregnation of polymer matrices has been attempted by a supercritical carbon dioxide-based process. Polymeric matrices are composed of polycaprolactone blends, where water-soluble polymers, polyethylene glycol, polyvinyl pyrrolidone, gelatin, and thermoplastic starch, have been employed to modulate the MSG release, making the devices potentially suitable for topical administrations. Two different techniques have been used to obtain the films: the first one is compression molding, producing compact and continuous structures, and the second one is electrospinning, producing membrane-like designs. A higher amount of MSG can be loaded into the polymeric matrix in the membrane-like structures since, in these films, the impregnation process is faster than in the case of compression molded films, where the carbon dioxide has firstly diffused and then released the active molecule. The type of water-soluble polymer influences the drug release rate: the blend polycaprolactone-gelatin gives a prolonged release potentially suitable for topical administration.

Drug affinity-responsive target stability unveils filamins as biological targets for artemetin, an anti-cancer flavonoid

Artemetin is a valuable 5-hydroxy-3,6,7,3′,4′-pentamethoxyflavone present in many different medicinal plants with very good oral bioavailability and drug-likeness values, owing to numerous bioactivities, such as anti-inflammatory and anti-cancer ones. Here, a multi-disciplinary plan has been settled and applied for identifying the artemetin target(s) to inspect its mechanism of action, based on drug affinity-responsive target stability and targeted limited proteolysis. Both approaches point to the disclosure of filamins A and B as direct artemetin targets in HeLa cell lysates, also giving detailed insights into the ligand/protein-binding sites. Interestingly, also 8-prenyl-artemetin, which is an artemetin more permeable semisynthetic analog, directly interacts with filamins A and B. Both compounds alter filamin conformation in living HeLa cells with an effect on cytoskeleton disassembly and on the disorganization of the F-actin filaments. Both the natural compound and its derivative are able to block cell migration, expectantly acting on tumor metastasis occurrence and development.

Plant hairy roots for the production of extracellular vesicles with antitumor bioactivity

Plant extracellular vesicles (EVs) concentrate and deliver different types of bioactive molecules in human cells and are excellent candidates for a next-generation drug delivery system. However, the lack of standard protocols for plant EV production and the natural variations of their biomolecular cargo pose serious limitation to their use as therapeutics. To overcome these issues, we set up a versatile and standardized procedure to purify plant EVs from hairy root (HR) cultures, a versatile biotechnological system, already successfully employed as source of bioactive molecules with pharmaceutical and nutraceutical relevance. Herewith, we report that HR of Salvia dominica represent an excellent platform for the production of plant EVs. In particular, EVs derived from S. dominica HRs are small round-shaped vesicles carrying typical EV-associated proteins such as cytoskeletal components, chaperon proteins and integral membrane proteins including the tetraspanin TET-7. Interestingly, the HR-derived EVs showed selective and strong pro-apoptotic activity in pancreatic and mammary cancer cells. These results reveal that plant hairy roots may be considered a new promising tool in plant biotechnology for the production of extracellular vesicles for human health.

A combined system for asbestos-cement waste degradation by dark fermentation and resulting supernatant valorization in anaerobic digestion

The use of biological processes for the treatment of asbestos cement waste (ACW) has gained interest in recent years. Nevertheless, this methodology is not yet consolidated because of the incomplete ACW conversion during the biological treatment and the consequent need for further treatments that generally require a high amount of energy and chemicals. In this study, the efficiency of both mesophilic and thermophilic dark fermentation (DF) fed with glucose in fed-batch conditions was assessed for ACW biological treatment. Both thermophilic and mesophilic DF of glucose resulted in a partial conversion of glucose into organic acids that successfully degraded all the asbestos fibers contained in an ACW sample. A hydrogen-rich biogas was produced as well: at the end of the mesophilic DF treatment 0.14 L_H2 g_glucose^-1 were obtained. In addition, the anaerobic digestion (AD) of the DF supernatants led to the production of 0.38 L_CH4 g_COD^-1.

The combination of mesoglycan and VEGF promotes skin wound repair by enhancing the activation of endothelial cells and fibroblasts and their cross-talk

Skin wound healing requires accurate therapeutic topical managements to accelerate tissue regeneration. Here, for the first time, we found that the association mesoglycan/VEGF has a strong pro-healing activity. In detail, this combination induces angiogenesis in human endothelial cells promoting in turn fibroblasts recruitment. These ones acquire a notable ability to invade the matrigel coating and to secrete an active form of metalloproteinase 2 in presence of endothelial cells treated with mesoglycan/VEGF. Next, by creating intrascapular lesions on the back of C57Bl6 mice, we observed that the topical treatments with the mesoglycan/VEGF promotes the closure of wounds more than the single substances beside the control represented by a saline solution. As revealed by eosin/hematoxylin staining of mice skin biopsies, treatment with the combination mesoglycan/VEGF allows the formation of a well-structured matrix with a significant number of new vessels. Immunofluorescence analyses have revealed the presence of endothelial cells at the closed region of wounds, as evaluated by CD31, VE-cadherin and fibronectin staining and of activated fibroblasts assessed by vimentin, col1A and FAP1α. These results encourage defining the association mesoglycan/VEGF to activate endothelial and fibroblast cell components in skin wound healing promoting the creation of new vessels and the deposition of granulation tissue.

The Procoagulant Activity of Emoxilane®: A New Appealing Therapeutic Use in Epistaxis of the Combination of Sodium Hyaluronate, Silver Salt, α-tocopherol and D-panthenol

Epistaxis is one of the most frequent hemorrhages resulting from local or systemic factors. Its management without hospitalization has prompted an interest in locally applied hemostatic agents. Generally, the therapy approaches involve sprays or creams acting as a physical barrier, even used as tampons or gauze. In this study, we have investigated the activity of Emoxilane^®, a combination of sodium hyaluronate, silver salt, α-tocopherol acetate and D-panthenol, which is known to be able to separately act in a different biological manner. Our in vitro results, obtained on endothelial and nasal epithelial cells, have shown that the association of these molecules presented a notable antioxidant activity mainly due to the α-tocopherol and D-panthenol and a significant antimicrobial role thanks to the silver compound. Moreover, remarkable hemostatic activity was found by evaluating plasmin inhibition attributable to the sodium hyaluronate. Interestingly, on human plasma, we have confirmed that Emoxilane^® strongly induced the increase of thrombin levels. These data suggest that the use of this association could represent an appealing pharmacological approach to actively induce hemostasis during epistaxis. Our future perspective will aim to the creation of a formulation for an easy topical application in the nose which is able to contrast the bleeding.

An online Sexual Health and Rehabilitation eClinic (TrueNTH SHAReClinic) for prostate cancer patients: a feasibility study

Purpose

The primary objective was to determine the feasibility of implementing the TrueNTH SHAReClinic as a pan-Canadian sexual health and rehabilitation intervention for patients treated for localized prostate cancer.

Methods

The feasibility study was designed to evaluate the accessibility and acceptability of the intervention. Participants from five institutions across Canada were enrolled to attend one pre-treatment and five follow-up online clinic visits over 1 year following their prostate cancer (PC) treatment.

Results

Sixty-five patients were enrolled in the intervention. Website analytics revealed that 71% completed the intervention in its entirety, including the educational modules, with an additional 10% completing more than half of the intervention. Five thousand eighty-three views of the educational modules were made along with 654 views of the health library items. Over 1500 messages were exchanged between participants and their sexual health coaches. At 12 months, the intervention received an overall average participant rating of 4.1 out of 5 on a single item satisfaction measure.

Conclusion

Results support the TrueNTH SHAReClinic as highly acceptable to participants as defined by intervention adherence and engagement. The TrueNTH SHAReClinic demonstrated promise for being a feasible and potentially resource-efficient approach to effectively improving the sexual well-being of patients after PC treatment.

Novel insights on the molecular mechanism of action of the anti-angiogenic pyrazolyl-urea GeGe-3 by functional proteomics

In recent years, 5-pyrazolyl-ureas have mostly been known for their attractive poly-pharmacological outline and, in particular, ethyl 1-(2-hydroxypentyl)-5-(3-(3-(trifluoromethyl) phenyl) ureido)-1H-pyrazole-4-carboxylate (named GeGe-3) has emerged as a capable anti-angiogenic compound. This paper examines its interactome by functional proteomics using a label-free mass spectrometry based platform, coupling Drug Affinity Responsive Target Stability and targeted Limited Proteolysis-Multiple Reaction Monitoring. Calreticulin has been recognized as the GeGe-3 principal target and this evidence has been supported by immunoblotting and in silico molecular docking. Furthermore, cell studies have shown that GeGe-3 lowers cell calcium mobilization, cytoskeleton organization and focal adhesion kinase expression, thus linking its biological potential to calreticulin binding and, ultimately, shedding light on the reasonable action mechanism of this molecule as an anti-angiogenic factor.

Mesoglycan exerts its fibrinolytic effect through the activation of annexin A2

Mesoglycan is a drug based on a mixture of glycosaminoglycans mainly used for the treatment of blood vessel diseases acting as antithrombotic and profibrinolytic drugs. Besides the numerous clinical studies, there is no information about its function on the fibrinolytic cascade. Here, we have elucidated the mechanism of action by which mesoglycan induces the activation of plasmin from endothelial cells. Surprisingly, by a proteomic analysis, we found that, following mesoglycan treatment, these cells show a notable amount of annexin A2 (ANXA2) at the plasma membrane. This protein has been widely associated with fibrinolysis and appears able to move to the membrane when phosphorylated. In our model, this translocation has proven to enhance cell migration, invasion, and angiogenesis. Furthermore, the interaction of mesoglycan with syndecan 4 (SDC4), a coreceptor belonging to the class of heparan sulfate proteoglycans, represents the upstream event of the ANXA2 behavior. Indeed, the activation of SDC4 triggers the motility of endothelial cells culminating in angiogenesis. Interestingly, mesoglycan can induce the release of plasmin in endothelial cell supernatants only in the presence of ANXA2. This evaluation suggests that mesoglycan triggers the formation of a chain mechanism starting from the activation of SDC4, and the related cascade of events, including src complex and PKCα activation, promoting the phosphorylation of ANXA2 and its translocation to plasma membrane. This indicates a connection among mesoglycan, SDC4-(PKCα-src), and ANXA2 which, in turn, links the tissue plasminogen activator bringing it closer to plasminogen. This latter is so cleaved to release the plasmin and degrade fibrin sleeves.

Mesoglycan connects Syndecan-4 and VEGFR2 through Annexin A1 and formyl peptide receptors to promote angiogenesis in vitro

Mesoglycan is a mixture of glycosaminoglycans (GAG) with fibrinolytic effects and the potential to enhance skin wound repair. Here, we have used endothelial cells isolated from wild‐type (WT) and Syndecan‐4 null (Sdc4‐/‐) C57BL/6 mice to demonstrate that mesoglycan promotes cell motility and in vitro angiogenesis acting on the co‐receptor Syndecan‐4 (SDC4). This latter is known to participate in the formation and release of extracellular vesicles (EVs). We characterized EVs released by HUVECs and assessed their effect on angiogenesis. Particularly, we focused on Annexin A1 (ANXA1) containing EVs, since they may contribute to tube formation via interactions with Formyl peptide receptors (FPRs). In our model, the bond ANXA1‐FPRs stimulates the release of vascular endothelial growth factor (VEGF‐A) that interacts with vascular endothelial receptor‐2 (VEGFR2) and activates the pathway enhancing cell motility in an autocrine manner, as shown by wound healing/invasion assays, and the induction of endothelial to mesenchymal transition (EndMT). Thus, we have shown for the first time that mesoglycan exerts its pro‐angiogenic effects in the healing process triggering the activation of the three interconnected molecular axis: mesoglycan‐SDC4, EVs‐ANXA1‐FPRs, and VEGF‐A‐VEGFR2.

The promising pro-healing role of the association of mesoglycan and lactoferrin on skin lesions

Skin wound repair represents an important topic for the therapeutic challenges. Many molecules are commonly used as active principles of topical devices to induce the correct tissue regeneration. Among these molecules, mesoglycan, a mixture of glycosaminoglycans, and the lactoferrin have recently aroused interest. Here, for the first time, we used mesoglycan/lactoferrin to treat the cell populations mainly involved in wound healing. We showed that human keratinocytes, fibroblasts and endothelial cells migrate and invade more rapidly when treated with the association. Moreover, we found that mesoglycan/lactoferrin, are able to trigger the differentiation process of keratinocytes, the switch of the fibroblasts into myofibroblasts, the acquisition of a mesenchymal phenotype for the endothelial cells which, in this way, start to form the capillary-like structures. Additionally, we proved that the well known antimicrobial behavior of lactoferrin encourages the inhibition of S. aureus and P. aeruginosa biofilm formation by the whole association, providing an appealing feature for this formulation. Finally, by the in vivo analysis, we showed that the mesoglycan/lactoferrin favors the closure of skin wounds performed on the mice back. Beside the decrease of the lesion diameters, by a confocal analysis of mice biopsies we found that the use of the association strongly promote cell activation underlying the correct tissue regeneration. These results encourage to further investigation aiming the development of a new topical patch that includes this association.

TFF1 Induces Aggregation and Reduces Motility of Helicobacter pylori

Gastric cancer is considered one of the most common malignancies in humans and Helicobacter pylori infection is the major environmental risk factor of gastric cancer development. Given the high spread of this bacterium whose infection is mostly asymptomatic, H. pylori colonization persists for a long time, becoming chronic and predisposing to malignant transformation. The first defensive barrier from bacterial infection is constituted by the gastric mucosa that secretes several protective factors, among which is the trefoil factor 1 (TFF1), that, as mucin 5AC, binds the bacterium. Even if the protective role of TFF1 is well-documented, the molecular mechanisms that confer a beneficial function to the interaction among TFF1 and H. pylori remain still unclear. Here we analyze the effects of this interaction on H. pylori at morphological and molecular levels by means of microscopic observation, chemiotaxis and motility assays and real-time PCR analysis. Our results show that TFF1 favors aggregation of H. pylori and significantly slows down the motility of the bacterium across the mucus. Such aggregates significantly reduce both flgE and flaB gene transcription compared with bacteria not incubated with TFF1. Finally, our results suggest that the interaction between TFF1 and the bacterium may explain the frequent persistence of H. pylori in the human host without inducing disease.

Annexin A1 Released in Extracellular Vesicles by Pancreatic Cancer Cells Activates Components of the Tumor Microenvironment, through Interaction with the Formyl-Peptide Receptors

Pancreatic cancer (PC) is one of the most aggressive cancers in the world. Several extracellular factors are involved in its development and metastasis to distant organs. In PC, the protein Annexin A1 (ANXA1) appears to be overexpressed and may be identified as an oncogenic factor, also because it is a component in tumor-deriving extracellular vesicles (EVs). Indeed, these microvesicles are known to nourish the tumor microenvironment. Once we evaluated the autocrine role of ANXA1-containing EVs on PC MIA PaCa-2 cells and their pro-angiogenic action, we investigated the ANXA1 paracrine effect on stromal cells like fibroblasts and endothelial ones. Concerning the analysis of fibroblasts, cell migration/invasion, cytoskeleton remodeling, and the different expression of specific protein markers, all features of the cell switching into myofibroblasts, were assessed after administration of wild type more than ANXA1 Knock-Out EVs. Interestingly, we demonstrated a mechanism by which the ANXA1-EVs complex can stimulate the activation of formyl peptide receptors (FPRs), triggering mesenchymal switches and cell motility on both fibroblasts and endothelial cells. Therefore, we highlighted the importance of ANXA1/EVs-FPR axes in PC progression as a vehicle of intercommunication tumor cells-stroma, suggesting a specific potential prognostic/diagnostic role of ANXA1, whether in soluble form or even if EVs are captured in PC.

Mesoglycan induces the secretion of microvesicles by keratinocytes able to activate human fibroblasts and endothelial cells: A novel mechanism in skin wound healing

Mesoglycan is a fibrinolytic compound but recently promising pro-healing effects in skin wound repair have been reported. Previously, we have showed that mesoglycan activates human keratinocytes, fibroblasts and endothelial cells and induces the secretion of microvesicles (EVs), particularly exosomes, from keratinocytes. These EVs may contribute to wound healing since they further activate cells generating an autocrine loop with a positive feedback. In this work, EVs isolated from keratinocytes, treated with mesoglycan, have been tested on human fibroblasts and endothelial cells. The in vitro investigation has been carried out through Wound-Healing/invasion assays to analyze cell motility and assess the differentiation process. Then, the formation of capillary-like structures by human endothelial cells has been performed to evaluate in vitro angiogenesis. We found that EVs secreted from keratinocytes treated with mesoglycan promote fibroblasts and endothelial cells migration and invasion. Furthermore, these receiving cells acquire a mesenchymal phenotype. Additionally, the angiogenesis appears strongly enhanced in presence of this kind of EVs. In conclusion, we show that EVs deriving from keratinocytes trigger a paracrine positive feedback able to further amplify the effects of mesoglycan. This mechanism adds up to the autocrine loop previously reported and culminates with the activation of fibroblasts and endothelial cells. Particularly, this activation is amplified by the action of growth factors as FGF-2 (Fibroblast Growth Factor-2) for the fibroblasts and by VEGF (Vascular Endothelial Growth Factor) for the endothelial cells.

Low copper availability limits Helicobacter infection in mice

Copper is an essential element for all living organisms; however, it becomes toxic at high concentrations due to its ability to participate in many redox reactions. This vital micronutrient balance plays an important role in the battle between host and pathogen, due to its use by the host to intoxicate pathogens. In this study, we explore the effects of copper deprivation on Helicobacter infection in mice using the copper chelator tetrathiomolybdate. Our results reveal that Helicobacter infection significantly reduces copper concentration in mice stomachs without affecting its circulating levels. Moreover, in copper-deprived mice, bacteria hardly colonize the epithelium and mice show less gastric damage in comparison with the infected ones. However, when the copper chelator is administered after infection, the condition of the mouse stomachs declines. This could be explained by the lower copper availability in tetrathiomolybdate-treated mice, which would reduce macrophages' action against the pathogen. In this scenario, we observe that the protective factor trefoil factor 1 is induced upon copper-deprived conditions, probably contributing to the inefficacy of infection, whereas, when the chelator is administered after infection, the gene is already silenced by bacteria and cannot be restored. In conclusion, our data suggest that Helicobacter takes advantage of gastric copper reducing its availability for the host and that copper levels have an impact on the outcome of infection.

PCL/Mesoglycan Devices Obtained by Supercritical Foaming and Impregnation

In this work, a one-shot process for the simultaneous foaming of polycaprolactone (PCL) and impregnation of mesoglycan (MSG) into the porous structure was successfully attempted. Supercritical carbon dioxide plays the role of the foaming agent with respect to PCL and of the solvent with respect to MSG. The main objective is to produce an innovative topical device for application on skin lesions, promoting prolonged pro-resolving effects. The obtained device offers a protective barrier to ensure a favorable and sterilized environment for the wound healing process. The impregnation kinetics revealed that a pressure of 17 MPa, a temperature of 35 °C, and a time of impregnation of 24 h assured a proper foaming of PCL in addition to the impregnation of the maximum amount of MSG; i.e., 0.22 mg_MSG/mg_PCL. After a preliminary study conducted on PCL granules used as brought, the MSG impregnation was performed at the optimized process conditions also on a PCL film, produced by compression molding, with the final goal of producing medical patches. Comparing the dissolution profiles in phosphate buffered saline solution (PBS) of pure MSG and MSG impregnated on foamed PCL, it was demonstrated that the release of MSG was significantly prolonged up to 70 times. Next, we performed functional assays of in vitro wound healing, cell invasion, and angiogenesis to evaluate the biological effects of the PCL-derived MSG. Interestingly, we found the ability of this composite system to promote the activation of human keratinocytes, fibroblasts, and endothelial cells, as the main actors of tissue regeneration, confirming what we previously showed for the MSG alone.

miR-196a Is Able to Restore the Aggressive Phenotype of Annexin A1 Knock-Out in Pancreatic Cancer Cells by CRISPR/Cas9 Genome Editing

Annexin A1 (ANXA1) is a Ca²⁺-binding protein that is involved in pancreatic cancer (PC) progression. It is able to mediate cytoskeletal organization maintaining a malignant phenotype. Our previous studies showed that ANXA1 Knock-Out (KO) MIA PaCa-2 cells partially lost their migratory and invasive capabilities and also the metastatization process appeared affected in vivo. Here, we investigated the microRNA (miRNA) profile in ANXA1 KO cells finding that the modification in miRNA expression suggests the significant involvement of ANXA1 in PC development. In this study, we focused on miR-196a which appeared down modulated in absence of ANXA1. This miRNA is a well known oncogenic factor in several tumour models and it is able to trigger the agents of the epithelial to mesenchymal transition (EMT), like ANXA1. Our results show that the reintroduction in ANXA1 KO cells of miR-196a through the mimic sequence restored the early aggressive phenotype of MIA PaCa-2. Then, ANXA1 seems to support the expression of miR-196a and its role. On the other hand, this miRNA is able to mediate cytoskeletal dynamics and other protein functions promoting PC cell migration and invasion. This work describes the correlation between ANXA1 and specific miRNA sequences, particularly miR-196a. These results could lead to further information on ANXA1 intracellular role in PC, explaining other aspects that are apart from its tumorigenic behaviour.

Effects of Prisma® Skin dermal regeneration device containing glycosaminoglycans on human keratinocytes and fibroblasts

Prisma® Skin is a new pharmaceutical device developed by Mediolanum Farmaceutici S.p.a. It includes alginates, hyaluronic acid and mainly mesoglycan. The latter is a natural glycosaminoglycan preparation containing chondroitin sulfate, dermatan sulfate, heparan sulfate and heparin and it is used in the treatment of vascular disease. Glycosaminoglycans may contribute to the re-epithelialization in the skin wound healing, as components of the extracellular matrix. Here we describe, for the first time, the effects of Prisma® Skin in in vitro cultures of adult epidermal keratinocytes and dermal fibroblasts. Once confirmed the lack of cytotoxicity by mesoglycan and Prisma® Skin, we have shown the increase of S and G2 phases of fibroblasts cell cycle distribution. We further report the strong induction of cell migration rate and invasion capability on both cell lines, two key processes of wound repair. In support of these results, we found significant cytoskeletal reorganization, following the treatments with mesoglycan and Prisma® Skin, as confirmed by the formation of F-actin stress fibers. Additionally, together with a significant reduction of E-cadherin, keratinocytes showed an increase of CD44 expression and the translocation of ezrin to the plasma membrane, suggesting the involvement of CD44/ERM (ezrin-radixin-moesin) pathway in the induction of the analyzed processes. Furthermore, as showed by immunofluorescence assay, fibroblasts treated with mesoglycan and Prisma® Skin exhibited the increase of Fibroblast Activated Protein α and a remarkable change in shape and orientation, two common features of reactive stromal fibroblasts. In all experiments Prisma® Skin was slightly more potent than mesoglycan. In conclusion, based on these findings we suggest that Prisma® Skin may be able to accelerate the healing process in venous skin ulcers, principally enhancing re-epithelialization and granulation processes.

Benzodiazepine Scaffold as Drug-like Molecular Simplification of FR235222: A Chemical Tool for Exploring HDAC Inhibition

BACKGROUND

Synthesis, computational study and biological evaluation of peptidomimetic analogues of FR235222 (3), a natural immunosuppressant and HDAC inhibitor, have been reported. These new compounds, bearing α-hydroxyketone moiety, as more stable zinc binding group (ZBG), were evaluated in vitro as HDAC inhibitors against the human HDACs isoforms 1-9 and in cellular antiproliferative assays on U937 human leukemia cell line. The 1,4-benzodiazepin-2,5-dione (BDZ), capping group and the natural ZBG, (S,R)-2-amino-9-hydroxy-8-oxodecanoic acid (Ahoda), were evaluated in order to probe HDAC inhibition and/or paralogue selectivity. Some of the new derivatives showed an interesting activity against a number of HDAC isozymes. The observed activity profile was rationalized by a computational assisted SAR study, in order to understand how the BDZ classes interact with the enzyme into the catalytic pocket. Despite its poor solubility, compound 17b showed significant antiproliferative profile and HDAC inhibition activity.

RESULT

In order to assess how the solubility issue could have affected the biological outcome, bioassay conditions were reproduced and quantification of precipitated particulate material was evaluated by turbidimetric and NMR studies together with physicochemical descriptors prediction. Thus, BDZ 17b has been chosen to be promising lead compounds for further optimization, in order to elucidate molecule- enzyme surface recognition.

Hypoxia regulates ANXA1 expression to support prostate cancer cell invasion and aggressiveness

Annexin A1 (ANXA1) is a Ca²⁺-binding protein overexpressed in the invasive stages of prostate cancer (PCa) development; however, its role in this tumor metastatization is largely unknown. Moreover, hypoxic conditions in solid tumors have been related to poor prognosis in PCa patients. We have previously demonstrated that ANXA1 is implicated in the acquisition of chemo-resistant features in DU145 PCa cells conferring them a mesenchymal/metastatic phenotype. In this study, we have investigated the mechanisms by which ANXA1 regulates metastatic behavior in LNCaP, DU145 and PC3 cells exposed to hypoxia. ANXA1 was differentially expressed by PCa cell lines in normoxia whereas hypoxic stimuli resulted in a significant increase of protein expression. Additionally, in low oxygen conditions ANXA1 was extensively secreted out-side the cells where its binding to formyl peptide receptors (FPRs) induced cell invasion. Loss and gain of function experiments performed by using the RNA interfering siANXA1 and an ANXA1 over-expressing plasmid (MF-ANXA1), also confirmed the leading role of the protein in modulating LNCaP, DU145 and PC3 cell invasiveness. Finally, ANXA1 played a crucial role in the regulation of cytoskeletal dynamics underlying metastatization process, such as the loss of adhesion molecules and the occurrence of the epithelial to mesenchymal transition (EMT). ANXA1 expression increased inversely to epithelial markers such as E-cadherin and cytokeratins 8 and 18 (CKs) and proportionally to mesenchymal ones such as vimentin, ezrin and moesin. Our results indicated that ANXA1 may be a key mediator of hypoxia-related metastasis-associated processes in PCa.

Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid

In this study, we have characterized the role of annexin A1 (ANXA1) in the acquisition and maintenance of stem-like/aggressive features in prostate cancer (PCa) cells comparing zoledronic acid (ZA)-resistant DU145R80 with their parental DU145 cells. ANXA1 is over-expressed in DU145R80 cells and its down-regulation abolishes their resistance to ZA. Moreover, ANXA1 induces DU145 and DU145R80 invasiveness acting through formyl peptide receptors (FPRs). Also, ANXA1 knockdown is able to inhibit epithelial to mesenchymal transition (EMT) and to reduce focal adhesion kinase (FAK) and metalloproteases (MMP)-2/9 expression in PCa cells. DU145R80 show a cancer stem cell (CSC)-like signature with a high expression of CSC markers including CD44, CD133, NANOG, Snail, Oct4 and ALDH7A1 and CSC-related genes as STAT3. Interestingly, ANXA1 knockdown induces these cells to revert from a putative prostate CSC to a more differentiated phenotype resembling DU145 PCa cell signature. Similar results are obtained concerning some drug resistance-related genes such as ATP Binding Cassette G2 (ABCG2) and Lung Resistant Protein (LRP). Our study provides new insights on the role of ANXA1 protein in PCa onset and progression.

Enablers and barriers in delivery of a cancer exercise program: the Canadian experience

BACKGROUND

Exercise is an important therapy to improve well-being after a cancer diagnosis. Accordingly, cancer-exercise programs have been developed to enhance clinical care; however, few programs exist in Canada. Expansion of cancer-exercise programming depends on an understanding of the process of program implementation, as well as enablers and barriers to program success. Gaining knowledge from current professionals in cancer-exercise programs could serve to facilitate the necessary understanding.

METHODS

Key personnel from Canadian cancer-exercise programs (n = 14) participated in semistructured interviews about program development and delivery.

RESULTS

Content analysis revealed 13 categories and 15 subcategories, which were grouped by three organizing domains: Program Implementation, Program Enablers, and Program Barriers. ■ Program Implementation (5 categories, 8 subcategories) included Program Initiation (clinical care extension, research project expansion, program champion), Funding, Participant Intake (avenues of awareness, health and safety assessment), Active Programming (monitoring patient exercise progress, health care practitioner involvement, program composition), and Discharge and Follow-up Plan.■ Program Enablers (4 categories, 4 subcategories) included Patient Participation (personalized care, supportive network, personal control, awareness of benefits), Partnerships, Advocacy and Support, and Program Characteristics.■ Program Barriers (4 categories, 3 subcategories) included Lack of Funding, Lack of Physician Support, Deterrents to Participation (fear and shame, program location, competing interests), and Disease Progression and Treatment.

CONCLUSIONS

Interview results provided insight into the development and delivery of cancer-exercise programs in Canada and could be used to guide future program development and expansion in Canada.

Risk perception and psychological morbidity in men at elevated risk for prostate cancer

OBJECTIVE

As prostate-specific antigen (psa) makes prostate cancer (pca) screening more accessible, more men are being identified with conditions that indicate high risk for developing pca, such as elevated psa and high-grade intraepithelial neoplasia (hgpin). In the present study, we assessed psychological well-being and risk perception in individuals with those high-risk conditions.

METHODS

A questionnaire consisting of a psychological symptom survey, a trait risk-aversion survey, and a cancer-specific risk perception survey was administered to 168 patients with early-stage localized pca and 69 patients at high risk for pca (n = 16 hgpin, n = 53 psa > 4 ng/mL). Analysis of variance was used to examine differences in psychological well-being and appraisal of risk between the groups.

RESULTS

Compared with the pca group, the high-risk group perceived their risk of dying from something other than pca to be significantly lower (p = 0.007). However, pca patients reported significantly more clinically important psychological symptoms.

CONCLUSIONS

The identification of prostate conditions that predict progression to cancer might not result in the psychological symptoms commonly experienced by pca patients, but does appear to be related to a distorted perception of the disease's mortal risk. Patients with pca experience reduced psychological well-being, but better understand the risks of pca recurrence and death. Education on the risks and outcomes of pca can help at-risk men to view health assessments with reduced worry.

Western blot expression of 5-lipoxygenase in the brain from striped dolphins (stenella coeruleoalba) and bottlenose dolphins (tursiops truncatus) with or without encephalitis/meningo-encephalitis of infectious nature

Dolphin Morbillivirus (DMV), Toxoplasma gondii and Brucella ceti are pathogens of major concern for wild cetaceans. Although a more or less severe encephalitis/meningo-encephalitis may occur in striped dolphins (Stenella coeruleoalba) and bottlenose dolphins (Tursiops truncatus) infected by the aforementioned agents, almost no information is available on the neuropathogenesis of brain lesions, including the neuronal and non-neuronal cells targeted during infection, along with the mechanisms underlying neurodegeneration. We analyzed 5-lipoxygenase (5-LOX) expression in the brain of 11 striped dolphins and 5 bottlenose dolphins, affected or not by encephalitic lesions of various degrees associated with DMV, T. gondii and B. ceti. All the 8 striped dolphins with encephalitis showed a more consistent 5-LOX expression than that observed in the 3 striped dolphins showing no morphologic evidence of brain lesions, with the most prominent band intensity being detected in a B. ceti-infected animal. Similar results were not obtained in T. gondii-infected vs T. gondii-uninfected bottlenose dolphins. Overall, the higher 5-LOX expression found in the brain of the 8 striped dolphins with infectious neuroinflammation is of interest, given that 5-LOX is a putative marker for neurodegeneration in human patients and in experimental animal models. Therefore, further investigation on this challenging issue is also needed in stranded cetaceans affected by central neuropathies.

Role of intracellular and extracellular annexin A1 in migration and invasion of human pancreatic carcinoma cells

BACKGROUND

Annexin A1 (ANXA1), a 37 kDa multifunctional protein, is over-expressed in tissues from patients of pancreatic carcinoma (PC) where the protein seems to be associated with malignant transformation and poor prognosis.

METHODS

The expression and localization of ANXA1 in MIA PaCa-2, PANC-1, BxPC-3 and CAPAN-2 cells were detected by Western Blotting and Immunofluorescence assay. Expression and activation of Formyl Peptide Receptors (FPRs) were shown through flow cytometry/PCR and FURA assay, respectively. To investigate the role of ANXA1 in PC cell migration and invasion, we performed in vitro wound-healing and matrigel invasion assays.

RESULTS

In all the analyzed PC cell lines, a huge expression and a variable localization of ANXA1 in sub-cellular compartments were observed. We confirmed the less aggressive phenotype of BxPC-3 and CAPAN-2 compared with PANC-1 and MIA PaCa-2 cells, through the evaluation of Epithelial-Mesenchymal Transition (EMT) markers. Then, we tested MIA PaCa-2 and PANC-1 cell migration and invasiveness rate which was inhibited by specific ANXA1 siRNAs. Both the cell lines expressed FPR-1 and -2. Ac2-26, an ANXA1 mimetic peptide, induced intracellular calcium release, consistent with FPR activation, and significantly increased cell migration/invasion rate. Interestingly, in MIA PaCa-2 cells we found a cleaved form of ANXA1 (33 kDa) that localizes at cellular membranes and is secreted outside the cells, as confirmed by MS analysis. The importance of the secreted form of ANXA1 in cellular motility was confirmed by the administration of ANXA1 blocking antibody that inhibited migration and invasion rate in MIA PaCa-2 but not in PANC-1 cells that lack the 33 kDa ANXA1 form and show a lower degree of invasiveness. Finally, the treatment of PANC-1 cells with MIA PaCa-2 supernatants significantly increased the migration rate of these cells.

CONCLUSION

This study provides new insights on the role of ANXA1 protein in PC progression. Our findings suggest that ANXA1 protein could regulate metastasis by favouring cell migration/invasion intracellularly, as cytoskeleton remodelling factor, and extracellularly like FPR ligand.

Annexin A1 induces skeletal muscle cell migration acting through formyl peptide receptors

Annexin A1 (ANXA1, lipocortin-1) is a glucocorticoid-regulated 37-kDa protein, so called since its main property is to bind (i.e. to annex) to cellular membranes in a Ca(2+)-dependent manner. Although ANXA1 has predominantly been studied in the context of immune responses and cancer, the protein can affect a larger variety of biological phenomena, including cell proliferation and migration. Our previous results show that endogenous ANXA1 positively modulates myoblast cell differentiation by promoting migration of satellite cells and, consequently, skeletal muscle differentiation. In this work, we have evaluated the hypothesis that ANXA1 is able to exert effects on myoblast cell migration acting through formyl peptide receptors (FPRs) following changes in its subcellular localization as in other cell types and tissues. The analysis of the subcellular localization of ANXA1 in C2C12 myoblasts during myogenic differentiation showed an interesting increase of extracellular ANXA1 starting from the initial phases of skeletal muscle cell differentiation. The investigation of intracellular Ca(2+) perturbation following exogenous administration of the ANXA1 N-terminal derived peptide Ac2-26 established the engagement of the FPRs which expression in C2C12 cells was assessed by qualitative PCR. Wound healing assay experiments showed that Ac2-26 peptide is able to increase migration of C2C12 skeletal muscle cells and to induce cell surface translocation and secretion of ANXA1. Our results suggest a role for ANXA1 as a highly versatile component in the signaling chains triggered by the proper calcium perturbation that takes place during active migration and differentiation or membrane repair since the protein is strongly redistributed onto the plasma membranes after an rapid increase of intracellular levels of Ca(2+). These properties indicate that ANXA1 may be involved in a novel repair mechanism for skeletal muscle and may have therapeutic implications with respect to the development of ANXA1 mimetics.

Annexin A1 N-terminal derived peptide Ac2-26 stimulates fibroblast migration in high glucose conditions

Deficient wound healing in diabetic patients is very frequent, but the cellular and molecular causes are poorly defined. In this study, we have evaluated whether Annexin A1 derived peptide Ac2-26 stimulates fibroblast migration in high glucose conditions. Using normal human skin fibroblasts WS1 in low glucose (LG) or high glucose (HG) we observed the enrichment of Annexin A1 protein at cell movement structures like lamellipodial extrusions and interestingly, a significant decrease in levels of the protein in HG conditions. The analysis of the translocation of Annexin A1 to cell membrane showed lower levels of Annexin A1 in both membrane pool and supernatants of WS1 cells treated with HG. Wound-healing assays using cell line transfected with Annexin A1 siRNAs indicated a slowing down in migration speed of cells suggesting that Annexin A1 has a role in the migration of WS1 cells. In order to analyze the role of extracellular Annexin A1 in cell migration, we have performed wound-healing assays using Ac2-26 showing that peptide was able to increase fibroblast cell migration in HG conditions. Experiments on the mobilization of intracellular calcium and analysis of p-ERK expression confirmed the activity of the FPR1 following stimulation with the peptide Ac2-26. A wound-healing assay on WS1 cells in the presence of the FPR agonist fMLP, of the FPR antagonist CsH and in the presence of Ac2-26 indicated that Annexin A1 influences fibroblast cell migration under HG conditions acting through FPR receptors whose expression was slightly increased in HG. In conclusion, these data demonstrate that (i) Annexin A1 is involved in migration of WS1 cells, through interaction with FPRs; (ii) N- terminal peptide of Annexin A1 Ac2-26 is able to stimulate direct migration of WS1 cells in high glucose treatment possibly due to the increased receptor expression observed in hyperglycemia conditions.

Measurement of ψ(2S) meson production in pp collisions at [Formula: see text]

The differential cross-section for the inclusive production of ψ(2S) mesons in pp collisions at [Formula: see text] has been measured with the LHCb detector. The data sample corresponds to an integrated luminosity of 36 pb^-1. The ψ(2S) mesons are reconstructed in the decay channels ψ(2S)→μ⁺μ^- and ψ(2S)→J/ψπ⁺π^-, with the J/ψ meson decaying into two muons. Results are presented both for promptly produced ψ(2S) mesons and for those originating from b-hadron decays. In the kinematic range p_T(ψ(2S))≤16 GeV/c and 2<y(ψ(2S))≤4.5 we measure [Formula: see text] where the last uncertainty on the prompt cross-section is due to the unknown ψ(2S) polarization. Recent QCD calculations are found to be in good agreement with our measurements. Combining the present result with the LHCb J/ψ measurements we determine the inclusive branching fraction [Formula: see text] where the last uncertainty is due to the [Formula: see text], [Formula: see text] and [Formula: see text] branching fraction uncertainties.

Annexin A1: novel roles in skeletal muscle biology

Annexin A1 (ANXA1, lipocortin-1) is the first characterized member of the annexin superfamily of proteins, so called since their main property is to bind (i.e., to annex) to cellular membranes in a Ca(2+) -dependent manner. ANXA1 has been involved in a broad range of molecular and cellular processes, including anti-inflammatory signalling, kinase activities in signal transduction, maintenance of cytoskeleton and extracellular matrix integrity, tissue growth, apoptosis, and differentiation. New insights show that endogenous ANXA1 positively modulates myoblast cell differentiation by promoting migration of satellite cells and, consequently, skeletal muscle differentiation. This suggests that ANXA1 may contribute to the regeneration of skeletal muscle tissue and may have therapeutic implications with respect to the development of ANXA1 mimetics.

Determination of the sign of the decay width difference in the B(s)(0) system

The interference between the K+ K- S-wave and P-wave amplitudes in B(s)(0) → J/ψK+ K- decays with the K+ K- pairs in the region around the ϕ(1020) resonance is used to determine the variation of the difference of the strong phase between these amplitudes as a function of K+ K- invariant mass. Combined with the results from our CP asymmetry measurement in B(s)(0) → J/ψϕ decays, we conclude that the B(s)(0) mass eigenstate that is almost CP = +1 is lighter and decays faster than the mass eigenstate that is almost CP = -1. This determines the sign of the decay width difference ΔΓ(s) ≡ Γ(L) - Γ(H) to be positive. Our result also resolves the ambiguity in the past measurements of the CP violating phase ϕ(s) to be close to zero rather than π. These conclusions are in agreement with the standard model expectations.

Opposite-side flavour tagging of B mesons at the LHCb experiment

The calibration and performance of the opposite-side flavour tagging algorithms used for the measurements of time-dependent asymmetries at the LHCb experiment are described. The algorithms have been developed using simulated events and optimized and calibrated with B⁺→J/ψK⁺, B⁰→J/ψK^∗0 and B⁰→D^∗-μ⁺ν_μ decay modes with 0.37 fb^-1 of data collected in pp collisions at [Formula: see text] during the 2011 physics run. The opposite-side tagging power is determined in the B⁺→J/ψK⁺ channel to be (2.10±0.08±0.24) %, where the first uncertainty is statistical and the second is systematic.

Measurement of production in collisions at [Formula: see text]

The production of ϒ(1S), ϒ(2S) and ϒ(3S) mesons in proton-proton collisions at the centre-of-mass energy of [Formula: see text] is studied with the LHCb detector. The analysis is based on a data sample of 25 pb-1 collected at the Large Hadron Collider. The ϒ mesons are reconstructed in the decay mode ϒ→μ+μ- and the signal yields are extracted from a fit to the μ+μ- invariant mass distributions. The differential production cross-sections times dimuon branching fractions are measured as a function of the ϒ transverse momentum pT and rapidity y, over the range pT <15 GeV/c and 2.0 Collapse

Key Words Collapse

MESH Headings Collapse

Grants Collapse

Affiliation(s)

The LHCb Collaboration />CERN, 1211 Geneva 23, Switzerland
R. Aaij />Nikhef National Institute for Subatomic Physics, Amsterdam, The Netherlands
C. Abellan Beteta />Universitat de Barcelona, Barcelona, Spain
B. Adeva />Universidad de Santiago de Compostela, Santiago de Compostela, Spain
M. Adinolfi />H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
C. Adrover />CPPM, Aix-Marseille Université, CNRS/IN2P3, Marseille, France
A. Affolder />Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
Z. Ajaltouni />Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
J. Albrecht />European Organization for Nuclear Research (CERN), Geneva, Switzerland
F. Alessio />European Organization for Nuclear Research (CERN), Geneva, Switzerland
M. Alexander />School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
G. Alkhazov />Petersburg Nuclear Physics Institute (PNPI), Gatchina, Russia
P. Alvarez Cartelle />Universidad de Santiago de Compostela, Santiago de Compostela, Spain
A. A. Alves />Sezione INFN di Roma La Sapienza, Roma, Italy
S. Amato />Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
Y. Amhis />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
J. Anderson />Physik-Institut, Universität Zürich, Zürich, Switzerland
R. B. Appleby />School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
O. Aquines Gutierrez />Max-Planck-Institut für Kernphysik (MPIK), Heidelberg, Germany
F. Archilli />Laboratori Nazionali dell’INFN di Frascati, Frascati, Italy />European Organization for Nuclear Research (CERN), Geneva, Switzerland
L. Arrabito />CC-IN2P3, CNRS/IN2P3, Lyon-Villeurbanne, France
A. Artamonov />Institute for High Energy Physics (IHEP), Protvino, Russia
M. Artuso />European Organization for Nuclear Research (CERN), Geneva, Switzerland />Syracuse University, Syracuse, NY United States
E. Aslanides />CPPM, Aix-Marseille Université, CNRS/IN2P3, Marseille, France
G. Auriemma />Sezione INFN di Roma La Sapienza, Roma, Italy
S. Bachmann />Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
J. J. Back />Department of Physics, University of Warwick, Coventry, United Kingdom
D. S. Bailey />School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
V. Balagura />Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia />European Organization for Nuclear Research (CERN), Geneva, Switzerland
W. Baldini />Sezione INFN di Ferrara, Ferrara, Italy
R. J. Barlow />School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
C. Barschel />European Organization for Nuclear Research (CERN), Geneva, Switzerland
S. Barsuk />LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
W. Barter />Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
A. Bates />School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
C. Bauer />Max-Planck-Institut für Kernphysik (MPIK), Heidelberg, Germany
Th. Bauer />Nikhef National Institute for Subatomic Physics, Amsterdam, The Netherlands
A. Bay />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
I. Bediaga />Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
S. Belogurov />Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
K. Belous />Institute for High Energy Physics (IHEP), Protvino, Russia
I. Belyaev />Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
E. Ben-Haim />LPNHE, Université Pierre et Marie Curie, Université Paris Diderot, CNRS/IN2P3, Paris, France
M. Benayoun />LPNHE, Université Pierre et Marie Curie, Université Paris Diderot, CNRS/IN2P3, Paris, France
G. Bencivenni />Laboratori Nazionali dell’INFN di Frascati, Frascati, Italy
S. Benson />School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
J. Benton />H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
R. Bernet />Physik-Institut, Universität Zürich, Zürich, Switzerland
M.-O. Bettler />Sezione INFN di Firenze, Firenze, Italy
M. van Beuzekom />Nikhef National Institute for Subatomic Physics, Amsterdam, The Netherlands
A. Bien />Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
S. Bifani />School of Physics, University College Dublin, Dublin, Ireland
T. Bird />School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
A. Bizzeti />Sezione INFN di Firenze, Firenze, Italy
P. M. Bjørnstad />School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
T. Blake />European Organization for Nuclear Research (CERN), Geneva, Switzerland
F. Blanc />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
C. Blanks />Imperial College London, London, United Kingdom
J. Blouw />Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
S. Blusk />Syracuse University, Syracuse, NY United States
A. Bobrov />Budker Institute of Nuclear Physics (SB RAS) and Novosibirsk State University, Novosibirsk, Russia
V. Bocci />Sezione INFN di Roma La Sapienza, Roma, Italy
A. Bondar />Budker Institute of Nuclear Physics (SB RAS) and Novosibirsk State University, Novosibirsk, Russia
N. Bondar />Petersburg Nuclear Physics Institute (PNPI), Gatchina, Russia
W. Bonivento />Sezione INFN di Cagliari, Cagliari, Italy
S. Borghi />School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom />School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
A. Borgia />Syracuse University, Syracuse, NY United States
T. J. V. Bowcock />Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
C. Bozzi />Sezione INFN di Ferrara, Ferrara, Italy
T. Brambach />Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
J. van den Brand />Nikhef National Institute for Subatomic Physics and Vrije Universiteit, Amsterdam, The Netherlands
J. Bressieux />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
D. Brett />School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
M. Britsch />Max-Planck-Institut für Kernphysik (MPIK), Heidelberg, Germany
T. Britton />Syracuse University, Syracuse, NY United States
N. H. Brook />H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
H. Brown />Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
K. de Bruyn />Nikhef National Institute for Subatomic Physics, Amsterdam, The Netherlands
A. Büchler-Germann />Physik-Institut, Universität Zürich, Zürich, Switzerland
I. Burducea />Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania
A. Bursche />Physik-Institut, Universität Zürich, Zürich, Switzerland
J. Buytaert />European Organization for Nuclear Research (CERN), Geneva, Switzerland
S. Cadeddu />Sezione INFN di Cagliari, Cagliari, Italy
O. Callot />LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
M. Calvi />Sezione INFN di Milano Bicocca, Milano, Italy
M. Calvo Gomez />Universitat de Barcelona, Barcelona, Spain
A. Camboni />Universitat de Barcelona, Barcelona, Spain
P. Campana />Laboratori Nazionali dell’INFN di Frascati, Frascati, Italy />European Organization for Nuclear Research (CERN), Geneva, Switzerland
A. Carbone />Sezione INFN di Bologna, Bologna, Italy
G. Carboni />Sezione INFN di Roma Tor Vergata, Roma, Italy
R. Cardinale />Sezione INFN di Genova, Genova, Italy />European Organization for Nuclear Research (CERN), Geneva, Switzerland
A. Cardini />Sezione INFN di Cagliari, Cagliari, Italy
L. Carson />Imperial College London, London, United Kingdom
K. Carvalho Akiba />Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
G. Casse />Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
M. Cattaneo />European Organization for Nuclear Research (CERN), Geneva, Switzerland
Ch. Cauet />Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
M. Charles />Department of Physics, University of Oxford, Oxford, United Kingdom
Ph. Charpentier />European Organization for Nuclear Research (CERN), Geneva, Switzerland
N. Chiapolini />Physik-Institut, Universität Zürich, Zürich, Switzerland
K. Ciba />European Organization for Nuclear Research (CERN), Geneva, Switzerland
X. Cid Vidal />Universidad de Santiago de Compostela, Santiago de Compostela, Spain
G. Ciezarek />Imperial College London, London, United Kingdom
P. E. L. Clarke />European Organization for Nuclear Research (CERN), Geneva, Switzerland />School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
M. Clemencic />European Organization for Nuclear Research (CERN), Geneva, Switzerland
H. V. Cliff />Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
J. Closier />European Organization for Nuclear Research (CERN), Geneva, Switzerland
C. Coca />Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania
V. Coco />Nikhef National Institute for Subatomic Physics, Amsterdam, The Netherlands
J. Cogan />CPPM, Aix-Marseille Université, CNRS/IN2P3, Marseille, France
P. Collins />European Organization for Nuclear Research (CERN), Geneva, Switzerland
A. Comerma-Montells />Universitat de Barcelona, Barcelona, Spain
F. Constantin />Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania
A. Contu />Department of Physics, University of Oxford, Oxford, United Kingdom
A. Cook />H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
M. Coombes />H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
G. Corti />European Organization for Nuclear Research (CERN), Geneva, Switzerland
B. Couturier />European Organization for Nuclear Research (CERN), Geneva, Switzerland
G. A. Cowan />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
R. Currie />School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
C. D’Ambrosio />European Organization for Nuclear Research (CERN), Geneva, Switzerland
P. David />LPNHE, Université Pierre et Marie Curie, Université Paris Diderot, CNRS/IN2P3, Paris, France
P. N. Y. David />Nikhef National Institute for Subatomic Physics, Amsterdam, The Netherlands
I. De Bonis />LAPP, Université de Savoie, CNRS/IN2P3, Annecy-Le-Vieux, France
S. De Capua />Sezione INFN di Roma Tor Vergata, Roma, Italy
M. De Cian />Physik-Institut, Universität Zürich, Zürich, Switzerland
F. De Lorenzi />School of Physics, University College Dublin, Dublin, Ireland
J. M. De Miranda />Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
L. De Paula />Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
P. De Simone />Laboratori Nazionali dell’INFN di Frascati, Frascati, Italy
D. Decamp />LAPP, Université de Savoie, CNRS/IN2P3, Annecy-Le-Vieux, France
M. Deckenhoff />Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
H. Degaudenzi />European Organization for Nuclear Research (CERN), Geneva, Switzerland />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
L. Del Buono />LPNHE, Université Pierre et Marie Curie, Université Paris Diderot, CNRS/IN2P3, Paris, France
C. Deplano />Sezione INFN di Cagliari, Cagliari, Italy
D. Derkach />Sezione INFN di Bologna, Bologna, Italy />European Organization for Nuclear Research (CERN), Geneva, Switzerland
O. Deschamps />Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
F. Dettori />Nikhef National Institute for Subatomic Physics and Vrije Universiteit, Amsterdam, The Netherlands
J. Dickens />Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
H. Dijkstra />European Organization for Nuclear Research (CERN), Geneva, Switzerland
P. Diniz Batista />Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
F. Domingo Bonal />Universitat de Barcelona, Barcelona, Spain
S. Donleavy />Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
F. Dordei />Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
A. Dosil Suárez />Universidad de Santiago de Compostela, Santiago de Compostela, Spain
D. Dossett />Department of Physics, University of Warwick, Coventry, United Kingdom
A. Dovbnya />NSC Kharkiv Institute of Physics and Technology (NSC KIPT), Kharkiv, Ukraine
F. Dupertuis />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
R. Dzhelyadin />Institute for High Energy Physics (IHEP), Protvino, Russia
A. Dziurda />Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
S. Easo />STFC Rutherford Appleton Laboratory, Didcot, United Kingdom
U. Egede />Imperial College London, London, United Kingdom
V. Egorychev />Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
S. Eidelman />Budker Institute of Nuclear Physics (SB RAS) and Novosibirsk State University, Novosibirsk, Russia
D. van Eijk />Nikhef National Institute for Subatomic Physics, Amsterdam, The Netherlands
F. Eisele />Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
S. Eisenhardt />School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
R. Ekelhof />Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
L. Eklund />School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
Ch. Elsasser />Physik-Institut, Universität Zürich, Zürich, Switzerland
D. Elsby />University of Birmingham, Birmingham, United Kingdom
D. Esperante Pereira />Universidad de Santiago de Compostela, Santiago de Compostela, Spain
A. Falabella />Sezione INFN di Bologna, Bologna, Italy />Sezione INFN di Ferrara, Ferrara, Italy
E. Fanchini />Sezione INFN di Milano Bicocca, Milano, Italy
C. Färber />Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
G. Fardell />School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
C. Farinelli />Nikhef National Institute for Subatomic Physics, Amsterdam, The Netherlands
S. Farry />School of Physics, University College Dublin, Dublin, Ireland
V. Fave />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
V. Fernandez Albor />Universidad de Santiago de Compostela, Santiago de Compostela, Spain
M. Ferro-Luzzi />European Organization for Nuclear Research (CERN), Geneva, Switzerland
S. Filippov />Institute for Nuclear Research of the Russian Academy of Sciences (INR RAN), Moscow, Russia
C. Fitzpatrick />School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
M. Fontana />Max-Planck-Institut für Kernphysik (MPIK), Heidelberg, Germany
F. Fontanelli />Sezione INFN di Genova, Genova, Italy
R. Forty />European Organization for Nuclear Research (CERN), Geneva, Switzerland
O. Francisco />Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
M. Frank />European Organization for Nuclear Research (CERN), Geneva, Switzerland
C. Frei />European Organization for Nuclear Research (CERN), Geneva, Switzerland
M. Frosini />Sezione INFN di Firenze, Firenze, Italy
S. Furcas />Sezione INFN di Milano Bicocca, Milano, Italy
A. Gallas Torreira />Universidad de Santiago de Compostela, Santiago de Compostela, Spain
D. Galli />Sezione INFN di Bologna, Bologna, Italy
M. Gandelman />Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
P. Gandini />Department of Physics, University of Oxford, Oxford, United Kingdom
Y. Gao />Center for High Energy Physics, Tsinghua University, Beijing, China
J-C. Garnier />European Organization for Nuclear Research (CERN), Geneva, Switzerland
J. Garofoli />Syracuse University, Syracuse, NY United States
J. Garra Tico />Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
L. Garrido />Universitat de Barcelona, Barcelona, Spain
D. Gascon />Universitat de Barcelona, Barcelona, Spain
C. Gaspar />European Organization for Nuclear Research (CERN), Geneva, Switzerland
R. Gauld />Department of Physics, University of Oxford, Oxford, United Kingdom
N. Gauvin />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
M. Gersabeck />European Organization for Nuclear Research (CERN), Geneva, Switzerland
T. Gershon />European Organization for Nuclear Research (CERN), Geneva, Switzerland />Department of Physics, University of Warwick, Coventry, United Kingdom
Ph. Ghez />LAPP, Université de Savoie, CNRS/IN2P3, Annecy-Le-Vieux, France
V. Gibson />Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
V. V. Gligorov />European Organization for Nuclear Research (CERN), Geneva, Switzerland
C. Göbel />Pontifícia Universidade Católica do Rio de Janeiro (PUC-Rio), Rio de Janeiro, Brazil
D. Golubkov />Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
A. Golutvin />Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia />European Organization for Nuclear Research (CERN), Geneva, Switzerland />Imperial College London, London, United Kingdom
A. Gomes />Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
H. Gordon />Department of Physics, University of Oxford, Oxford, United Kingdom
M. Grabalosa Gándara />Universitat de Barcelona, Barcelona, Spain
R. Graciani Diaz />Universitat de Barcelona, Barcelona, Spain
L. A. Granado Cardoso />European Organization for Nuclear Research (CERN), Geneva, Switzerland
E. Graugés />Universitat de Barcelona, Barcelona, Spain
G. Graziani />Sezione INFN di Firenze, Firenze, Italy
A. Grecu />Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania
E. Greening />Department of Physics, University of Oxford, Oxford, United Kingdom
S. Gregson />Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
B. Gui />Syracuse University, Syracuse, NY United States
E. Gushchin />Institute for Nuclear Research of the Russian Academy of Sciences (INR RAN), Moscow, Russia
Yu. Guz />Institute for High Energy Physics (IHEP), Protvino, Russia
T. Gys />European Organization for Nuclear Research (CERN), Geneva, Switzerland
C. Hadjivasiliou />Syracuse University, Syracuse, NY United States
G. Haefeli />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
C. Haen />European Organization for Nuclear Research (CERN), Geneva, Switzerland
S. C. Haines />Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
T. Hampson />H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
S. Hansmann-Menzemer />Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
R. Harji />Imperial College London, London, United Kingdom
N. Harnew />Department of Physics, University of Oxford, Oxford, United Kingdom
J. Harrison />School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
P. F. Harrison />Department of Physics, University of Warwick, Coventry, United Kingdom
T. Hartmann />Physikalisches Institut, Universität Rostock, Rostock, Germany
J. He />LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
V. Heijne />Nikhef National Institute for Subatomic Physics, Amsterdam, The Netherlands
K. Hennessy />Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
P. Henrard />Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
J. A. Hernando Morata />Universidad de Santiago de Compostela, Santiago de Compostela, Spain
E. van Herwijnen />European Organization for Nuclear Research (CERN), Geneva, Switzerland
E. Hicks />Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
K. Holubyev />Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
P. Hopchev />LAPP, Université de Savoie, CNRS/IN2P3, Annecy-Le-Vieux, France
W. Hulsbergen />Nikhef National Institute for Subatomic Physics, Amsterdam, The Netherlands
P. Hunt />Department of Physics, University of Oxford, Oxford, United Kingdom
T. Huse />Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
R. S. Huston />School of Physics, University College Dublin, Dublin, Ireland
D. Hutchcroft />Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
D. Hynds />School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
V. Iakovenko />Institute for Nuclear Research of the National Academy of Sciences (KINR), Kyiv, Ukraine
P. Ilten />School of Physics, University College Dublin, Dublin, Ireland
J. Imong />H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
R. Jacobsson />European Organization for Nuclear Research (CERN), Geneva, Switzerland
A. Jaeger />Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
M. Jahjah Hussein />Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
E. Jans />Nikhef National Institute for Subatomic Physics, Amsterdam, The Netherlands
F. Jansen />Nikhef National Institute for Subatomic Physics, Amsterdam, The Netherlands
P. Jaton />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
B. Jean-Marie />LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
F. Jing />Center for High Energy Physics, Tsinghua University, Beijing, China
M. John />Department of Physics, University of Oxford, Oxford, United Kingdom
D. Johnson />Department of Physics, University of Oxford, Oxford, United Kingdom
C. R. Jones />Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
B. Jost />European Organization for Nuclear Research (CERN), Geneva, Switzerland
M. Kaballo />Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
S. Kandybei />NSC Kharkiv Institute of Physics and Technology (NSC KIPT), Kharkiv, Ukraine
M. Karacson />European Organization for Nuclear Research (CERN), Geneva, Switzerland
T. M. Karbach />Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
J. Keaveney />School of Physics, University College Dublin, Dublin, Ireland
I. R. Kenyon />University of Birmingham, Birmingham, United Kingdom
U. Kerzel />European Organization for Nuclear Research (CERN), Geneva, Switzerland
T. Ketel />Nikhef National Institute for Subatomic Physics and Vrije Universiteit, Amsterdam, The Netherlands
A. Keune />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
B. Khanji />CPPM, Aix-Marseille Université, CNRS/IN2P3, Marseille, France
Y. M. Kim />School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
M. Knecht />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
R. F. Koopman />Nikhef National Institute for Subatomic Physics and Vrije Universiteit, Amsterdam, The Netherlands
P. Koppenburg />Nikhef National Institute for Subatomic Physics, Amsterdam, The Netherlands
M. Korolev />Institute of Nuclear Physics, Moscow State University (SINP MSU), Moscow, Russia
A. Kozlinskiy />Nikhef National Institute for Subatomic Physics, Amsterdam, The Netherlands
L. Kravchuk />Institute for Nuclear Research of the Russian Academy of Sciences (INR RAN), Moscow, Russia
K. Kreplin />Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
M. Kreps />Department of Physics, University of Warwick, Coventry, United Kingdom
G. Krocker />Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
P. Krokovny />Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
F. Kruse />Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
K. Kruzelecki />European Organization for Nuclear Research (CERN), Geneva, Switzerland
M. Kucharczyk />Sezione INFN di Milano Bicocca, Milano, Italy />Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland />European Organization for Nuclear Research (CERN), Geneva, Switzerland
T. Kvaratskheliya />Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia />European Organization for Nuclear Research (CERN), Geneva, Switzerland
V. N. La Thi />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
D. Lacarrere />European Organization for Nuclear Research (CERN), Geneva, Switzerland
G. Lafferty />School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
A. Lai />Sezione INFN di Cagliari, Cagliari, Italy
D. Lambert />School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
R. W. Lambert />Nikhef National Institute for Subatomic Physics and Vrije Universiteit, Amsterdam, The Netherlands
E. Lanciotti />European Organization for Nuclear Research (CERN), Geneva, Switzerland
G. Lanfranchi />Laboratori Nazionali dell’INFN di Frascati, Frascati, Italy
C. Langenbruch />Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
T. Latham />Department of Physics, University of Warwick, Coventry, United Kingdom
C. Lazzeroni />University of Birmingham, Birmingham, United Kingdom
R. Le Gac />CPPM, Aix-Marseille Université, CNRS/IN2P3, Marseille, France
J. van Leerdam />Nikhef National Institute for Subatomic Physics, Amsterdam, The Netherlands
J.-P. Lees />LAPP, Université de Savoie, CNRS/IN2P3, Annecy-Le-Vieux, France
R. Lefèvre />Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
A. Leflat />Institute of Nuclear Physics, Moscow State University (SINP MSU), Moscow, Russia />European Organization for Nuclear Research (CERN), Geneva, Switzerland
J. Lefrançois />LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
O. Leroy />CPPM, Aix-Marseille Université, CNRS/IN2P3, Marseille, France
T. Lesiak />Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
L. Li />Center for High Energy Physics, Tsinghua University, Beijing, China
L. Li Gioi />Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
M. Lieng />Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
M. Liles />Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
R. Lindner />European Organization for Nuclear Research (CERN), Geneva, Switzerland
C. Linn />Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
B. Liu />Center for High Energy Physics, Tsinghua University, Beijing, China
G. Liu />European Organization for Nuclear Research (CERN), Geneva, Switzerland
J. von Loeben />Sezione INFN di Milano Bicocca, Milano, Italy
J. H. Lopes />Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
E. Lopez Asamar />Universitat de Barcelona, Barcelona, Spain
N. Lopez-March />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
H. Lu />Center for High Energy Physics, Tsinghua University, Beijing, China
J. Luisier />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
A. Mac Raighne />School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
F. Machefert />LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
I. V. Machikhiliyan />LAPP, Université de Savoie, CNRS/IN2P3, Annecy-Le-Vieux, France />Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
F. Maciuc />Max-Planck-Institut für Kernphysik (MPIK), Heidelberg, Germany
O. Maev />Petersburg Nuclear Physics Institute (PNPI), Gatchina, Russia />European Organization for Nuclear Research (CERN), Geneva, Switzerland
J. Magnin />Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
S. Malde />Department of Physics, University of Oxford, Oxford, United Kingdom
R. M. D. Mamunur />European Organization for Nuclear Research (CERN), Geneva, Switzerland
G. Manca />Sezione INFN di Cagliari, Cagliari, Italy
G. Mancinelli />CPPM, Aix-Marseille Université, CNRS/IN2P3, Marseille, France
N. Mangiafave />Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
U. Marconi />Sezione INFN di Bologna, Bologna, Italy
R. Märki />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
J. Marks />Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
G. Martellotti />Sezione INFN di Roma La Sapienza, Roma, Italy
A. Martens />LPNHE, Université Pierre et Marie Curie, Université Paris Diderot, CNRS/IN2P3, Paris, France
L. Martin />Department of Physics, University of Oxford, Oxford, United Kingdom
A. Martín Sánchez />LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
D. Martinez Santos />European Organization for Nuclear Research (CERN), Geneva, Switzerland
A. Massafferri />Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
Z. Mathe />School of Physics, University College Dublin, Dublin, Ireland
C. Matteuzzi />Sezione INFN di Milano Bicocca, Milano, Italy
M. Matveev />Petersburg Nuclear Physics Institute (PNPI), Gatchina, Russia
E. Maurice />CPPM, Aix-Marseille Université, CNRS/IN2P3, Marseille, France
B. Maynard />Syracuse University, Syracuse, NY United States
A. Mazurov />Sezione INFN di Ferrara, Ferrara, Italy />Institute for Nuclear Research of the Russian Academy of Sciences (INR RAN), Moscow, Russia />European Organization for Nuclear Research (CERN), Geneva, Switzerland
G. McGregor />School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
R. McNulty />School of Physics, University College Dublin, Dublin, Ireland
M. Meissner />Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
M. Merk />Nikhef National Institute for Subatomic Physics, Amsterdam, The Netherlands
J. Merkel />Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
R. Messi />Sezione INFN di Roma Tor Vergata, Roma, Italy
S. Miglioranzi />European Organization for Nuclear Research (CERN), Geneva, Switzerland
D. A. Milanes />Sezione INFN di Bari, Bari, Italy
M.-N. Minard />LAPP, Université de Savoie, CNRS/IN2P3, Annecy-Le-Vieux, France
J. Molina Rodriguez />Pontifícia Universidade Católica do Rio de Janeiro (PUC-Rio), Rio de Janeiro, Brazil
S. Monteil />Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
D. Moran />School of Physics, University College Dublin, Dublin, Ireland
P. Morawski />Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
R. Mountain />Syracuse University, Syracuse, NY United States
I. Mous />Nikhef National Institute for Subatomic Physics, Amsterdam, The Netherlands
F. Muheim />School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
K. Müller />Physik-Institut, Universität Zürich, Zürich, Switzerland
R. Muresan />Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania
B. Muryn />AGH University of Science and Technology, Kraków, Poland
B. Muster />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
M. Musy />Universitat de Barcelona, Barcelona, Spain
J. Mylroie-Smith />Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
P. Naik />H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
T. Nakada />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
R. Nandakumar />STFC Rutherford Appleton Laboratory, Didcot, United Kingdom
I. Nasteva />Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
M. Nedos />Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
M. Needham />School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
N. Neufeld />European Organization for Nuclear Research (CERN), Geneva, Switzerland
A. D. Nguyen />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
C. Nguyen-Mau />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
M. Nicol />LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
V. Niess />Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
N. Nikitin />Institute of Nuclear Physics, Moscow State University (SINP MSU), Moscow, Russia
A. Nomerotski />European Organization for Nuclear Research (CERN), Geneva, Switzerland />Department of Physics, University of Oxford, Oxford, United Kingdom
A. Novoselov />Institute for High Energy Physics (IHEP), Protvino, Russia
A. Oblakowska-Mucha />AGH University of Science and Technology, Kraków, Poland
V. Obraztsov />Institute for High Energy Physics (IHEP), Protvino, Russia
S. Oggero />Nikhef National Institute for Subatomic Physics, Amsterdam, The Netherlands
S. Ogilvy />School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
O. Okhrimenko />Institute for Nuclear Research of the National Academy of Sciences (KINR), Kyiv, Ukraine
R. Oldeman />Sezione INFN di Cagliari, Cagliari, Italy />European Organization for Nuclear Research (CERN), Geneva, Switzerland
M. Orlandea />Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania
J. M. Otalora Goicochea />Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
P. Owen />Imperial College London, London, United Kingdom
K. Pal />Syracuse University, Syracuse, NY United States
J. Palacios />Physik-Institut, Universität Zürich, Zürich, Switzerland
A. Palano />Sezione INFN di Bari, Bari, Italy
M. Palutan />Laboratori Nazionali dell’INFN di Frascati, Frascati, Italy
J. Panman />European Organization for Nuclear Research (CERN), Geneva, Switzerland
A. Papanestis />STFC Rutherford Appleton Laboratory, Didcot, United Kingdom
M. Pappagallo />School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
C. Parkes />School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
C. J. Parkinson />Imperial College London, London, United Kingdom
G. Passaleva />Sezione INFN di Firenze, Firenze, Italy
G. D. Patel />Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
M. Patel />Imperial College London, London, United Kingdom
S. K. Paterson />Imperial College London, London, United Kingdom
G. N. Patrick />STFC Rutherford Appleton Laboratory, Didcot, United Kingdom
C. Patrignani />Sezione INFN di Genova, Genova, Italy
C. Pavel-Nicorescu />Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania
A. Pazos Alvarez />Universidad de Santiago de Compostela, Santiago de Compostela, Spain
A. Pellegrino />Nikhef National Institute for Subatomic Physics, Amsterdam, The Netherlands
G. Penso />Sezione INFN di Roma La Sapienza, Roma, Italy
M. Pepe Altarelli />European Organization for Nuclear Research (CERN), Geneva, Switzerland
S. Perazzini />Sezione INFN di Bologna, Bologna, Italy
D. L. Perego />Sezione INFN di Milano Bicocca, Milano, Italy
E. Perez Trigo />Universidad de Santiago de Compostela, Santiago de Compostela, Spain
A. Pérez-Calero Yzquierdo />Universitat de Barcelona, Barcelona, Spain
P. Perret />Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
M. Perrin-Terrin />CPPM, Aix-Marseille Université, CNRS/IN2P3, Marseille, France
G. Pessina />Sezione INFN di Milano Bicocca, Milano, Italy
A. Petrella />Sezione INFN di Ferrara, Ferrara, Italy />European Organization for Nuclear Research (CERN), Geneva, Switzerland
A. Petrolini />Sezione INFN di Genova, Genova, Italy
A. Phan />Syracuse University, Syracuse, NY United States
E. Picatoste Olloqui />Universitat de Barcelona, Barcelona, Spain
B. Pie Valls />Universitat de Barcelona, Barcelona, Spain
B. Pietrzyk />LAPP, Université de Savoie, CNRS/IN2P3, Annecy-Le-Vieux, France
T. Pilař />Department of Physics, University of Warwick, Coventry, United Kingdom
D. Pinci />Sezione INFN di Roma La Sapienza, Roma, Italy
R. Plackett />School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
S. Playfer />School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
M. Plo Casasus />Universidad de Santiago de Compostela, Santiago de Compostela, Spain
G. Polok />Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
A. Poluektov />Budker Institute of Nuclear Physics (SB RAS) and Novosibirsk State University, Novosibirsk, Russia />Department of Physics, University of Warwick, Coventry, United Kingdom
E. Polycarpo />Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
D. Popov />Max-Planck-Institut für Kernphysik (MPIK), Heidelberg, Germany
B. Popovici />Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania
C. Potterat />Universitat de Barcelona, Barcelona, Spain
A. Powell />Department of Physics, University of Oxford, Oxford, United Kingdom
J. Prisciandaro />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
V. Pugatch />Institute for Nuclear Research of the National Academy of Sciences (KINR), Kyiv, Ukraine
A. Puig Navarro />Universitat de Barcelona, Barcelona, Spain
W. Qian />Syracuse University, Syracuse, NY United States
J. H. Rademacker />H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
B. Rakotomiaramanana />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
M. S. Rangel />Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
I. Raniuk />NSC Kharkiv Institute of Physics and Technology (NSC KIPT), Kharkiv, Ukraine
G. Raven />Nikhef National Institute for Subatomic Physics and Vrije Universiteit, Amsterdam, The Netherlands
S. Redford />Department of Physics, University of Oxford, Oxford, United Kingdom
M. M. Reid />Department of Physics, University of Warwick, Coventry, United Kingdom
A. C. dos Reis />Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
S. Ricciardi />STFC Rutherford Appleton Laboratory, Didcot, United Kingdom
A. Richards />Imperial College London, London, United Kingdom
K. Rinnert />Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
D. A. Roa Romero />Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
P. Robbe />LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
E. Rodrigues />School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom />School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
F. Rodrigues />Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
P. Rodriguez Perez />Universidad de Santiago de Compostela, Santiago de Compostela, Spain
G. J. Rogers />Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
S. Roiser />European Organization for Nuclear Research (CERN), Geneva, Switzerland
V. Romanovsky />Institute for High Energy Physics (IHEP), Protvino, Russia
M. Rosello />Universitat de Barcelona, Barcelona, Spain
J. Rouvinet />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
T. Ruf />European Organization for Nuclear Research (CERN), Geneva, Switzerland
H. Ruiz />Universitat de Barcelona, Barcelona, Spain
G. Sabatino />Sezione INFN di Roma Tor Vergata, Roma, Italy
J. J. Saborido Silva />Universidad de Santiago de Compostela, Santiago de Compostela, Spain
N. Sagidova />Petersburg Nuclear Physics Institute (PNPI), Gatchina, Russia
P. Sail />School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
B. Saitta />Sezione INFN di Cagliari, Cagliari, Italy
C. Salzmann />Physik-Institut, Universität Zürich, Zürich, Switzerland
M. Sannino />Sezione INFN di Genova, Genova, Italy
R. Santacesaria />Sezione INFN di Roma La Sapienza, Roma, Italy
C. Santamarina Rios />Universidad de Santiago de Compostela, Santiago de Compostela, Spain
R. Santinelli />European Organization for Nuclear Research (CERN), Geneva, Switzerland
E. Santovetti />Sezione INFN di Roma Tor Vergata, Roma, Italy
M. Sapunov />CPPM, Aix-Marseille Université, CNRS/IN2P3, Marseille, France
A. Sarti />Laboratori Nazionali dell’INFN di Frascati, Frascati, Italy
C. Satriano />Sezione INFN di Roma La Sapienza, Roma, Italy
A. Satta />Sezione INFN di Roma Tor Vergata, Roma, Italy
M. Savrie />Sezione INFN di Ferrara, Ferrara, Italy
D. Savrina />Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
P. Schaack />Imperial College London, London, United Kingdom
M. Schiller />Nikhef National Institute for Subatomic Physics and Vrije Universiteit, Amsterdam, The Netherlands
S. Schleich />Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
M. Schlupp />Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
M. Schmelling />Max-Planck-Institut für Kernphysik (MPIK), Heidelberg, Germany
B. Schmidt />European Organization for Nuclear Research (CERN), Geneva, Switzerland
O. Schneider />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
A. Schopper />European Organization for Nuclear Research (CERN), Geneva, Switzerland
M.-H. Schune />LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
R. Schwemmer />European Organization for Nuclear Research (CERN), Geneva, Switzerland
B. Sciascia />Laboratori Nazionali dell’INFN di Frascati, Frascati, Italy
A. Sciubba />Laboratori Nazionali dell’INFN di Frascati, Frascati, Italy
M. Seco />Universidad de Santiago de Compostela, Santiago de Compostela, Spain
A. Semennikov />Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
K. Senderowska />AGH University of Science and Technology, Kraków, Poland
I. Sepp />Imperial College London, London, United Kingdom
N. Serra />Physik-Institut, Universität Zürich, Zürich, Switzerland
J. Serrano />CPPM, Aix-Marseille Université, CNRS/IN2P3, Marseille, France
P. Seyfert />Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
M. Shapkin />Institute for High Energy Physics (IHEP), Protvino, Russia
I. Shapoval />European Organization for Nuclear Research (CERN), Geneva, Switzerland />NSC Kharkiv Institute of Physics and Technology (NSC KIPT), Kharkiv, Ukraine
P. Shatalov />Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
Y. Shcheglov />Petersburg Nuclear Physics Institute (PNPI), Gatchina, Russia
T. Shears />Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
L. Shekhtman />Budker Institute of Nuclear Physics (SB RAS) and Novosibirsk State University, Novosibirsk, Russia
O. Shevchenko />NSC Kharkiv Institute of Physics and Technology (NSC KIPT), Kharkiv, Ukraine
V. Shevchenko />Institute of Theoretical and Experimental Physics (ITEP), Moscow, Russia
A. Shires />Imperial College London, London, United Kingdom
R. Silva Coutinho />Department of Physics, University of Warwick, Coventry, United Kingdom
T. Skwarnicki />Syracuse University, Syracuse, NY United States
N. A. Smith />Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
E. Smith />STFC Rutherford Appleton Laboratory, Didcot, United Kingdom />Department of Physics, University of Oxford, Oxford, United Kingdom
K. Sobczak />Clermont Université, Université Blaise Pascal, CNRS/IN2P3, LPC, Clermont-Ferrand, France
F. J. P. Soler />School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
A. Solomin />H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
F. Soomro />Laboratori Nazionali dell’INFN di Frascati, Frascati, Italy />European Organization for Nuclear Research (CERN), Geneva, Switzerland
B. Souza De Paula />Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
B. Spaan />Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
A. Sparkes />School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
P. Spradlin />School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
F. Stagni />European Organization for Nuclear Research (CERN), Geneva, Switzerland
S. Stahl />Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
O. Steinkamp />Physik-Institut, Universität Zürich, Zürich, Switzerland
S. Stoica />Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania
S. Stone />European Organization for Nuclear Research (CERN), Geneva, Switzerland />Syracuse University, Syracuse, NY United States
B. Storaci />Nikhef National Institute for Subatomic Physics, Amsterdam, The Netherlands
M. Straticiuc />Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania
U. Straumann />Physik-Institut, Universität Zürich, Zürich, Switzerland
V. K. Subbiah />European Organization for Nuclear Research (CERN), Geneva, Switzerland
S. Swientek />Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
M. Szczekowski />Soltan Institute for Nuclear Studies, Warsaw, Poland
P. Szczypka />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
T. Szumlak />AGH University of Science and Technology, Kraków, Poland
S. T’Jampens />LAPP, Université de Savoie, CNRS/IN2P3, Annecy-Le-Vieux, France
E. Teodorescu />Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania
F. Teubert />European Organization for Nuclear Research (CERN), Geneva, Switzerland
C. Thomas />Department of Physics, University of Oxford, Oxford, United Kingdom
E. Thomas />European Organization for Nuclear Research (CERN), Geneva, Switzerland
J. van Tilburg />Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
V. Tisserand />LAPP, Université de Savoie, CNRS/IN2P3, Annecy-Le-Vieux, France
M. Tobin />Physik-Institut, Universität Zürich, Zürich, Switzerland
S. Topp-Joergensen />Department of Physics, University of Oxford, Oxford, United Kingdom
N. Torr />Department of Physics, University of Oxford, Oxford, United Kingdom
E. Tournefier />LAPP, Université de Savoie, CNRS/IN2P3, Annecy-Le-Vieux, France />Imperial College London, London, United Kingdom
S. Tourneur />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
M. T. Tran />Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
A. Tsaregorodtsev />CPPM, Aix-Marseille Université, CNRS/IN2P3, Marseille, France
N. Tuning />Nikhef National Institute for Subatomic Physics, Amsterdam, The Netherlands
M. Ubeda Garcia />European Organization for Nuclear Research (CERN), Geneva, Switzerland
A. Ukleja />Soltan Institute for Nuclear Studies, Warsaw, Poland
P. Urquijo />Syracuse University, Syracuse, NY United States
U. Uwer />Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
V. Vagnoni />Sezione INFN di Bologna, Bologna, Italy
G. Valenti />Sezione INFN di Bologna, Bologna, Italy
R. Vazquez Gomez />Universitat de Barcelona, Barcelona, Spain
P. Vazquez Regueiro />Universidad de Santiago de Compostela, Santiago de Compostela, Spain
S. Vecchi />Sezione INFN di Ferrara, Ferrara, Italy
J. J. Velthuis />H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
M. Veltri />Sezione INFN di Firenze, Firenze, Italy
B. Viaud />LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
I. Videau />LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
D. Vieira />Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
X. Vilasis-Cardona />Universitat de Barcelona, Barcelona, Spain
J. Visniakov />Universidad de Santiago de Compostela, Santiago de Compostela, Spain
A. Vollhardt />Physik-Institut, Universität Zürich, Zürich, Switzerland
D. Volyanskyy />Max-Planck-Institut für Kernphysik (MPIK), Heidelberg, Germany
D. Voong />H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
A. Vorobyev />Petersburg Nuclear Physics Institute (PNPI), Gatchina, Russia
H. Voss />Max-Planck-Institut für Kernphysik (MPIK), Heidelberg, Germany
S. Wandernoth />Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
J. Wang />Syracuse University, Syracuse, NY United States
D. R. Ward />Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
N. K. Watson />University of Birmingham, Birmingham, United Kingdom
A. D. Webber />School of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
D. Websdale />Imperial College London, London, United Kingdom
M. Whitehead />Department of Physics, University of Warwick, Coventry, United Kingdom
D. Wiedner />Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
L. Wiggers />Nikhef National Institute for Subatomic Physics, Amsterdam, The Netherlands
G. Wilkinson />Department of Physics, University of Oxford, Oxford, United Kingdom
M. P. Williams />Department of Physics, University of Warwick, Coventry, United Kingdom />STFC Rutherford Appleton Laboratory, Didcot, United Kingdom
M. Williams />Imperial College London, London, United Kingdom
F. F. Wilson />STFC Rutherford Appleton Laboratory, Didcot, United Kingdom
J. Wishahi />Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
M. Witek />Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
W. Witzeling />European Organization for Nuclear Research (CERN), Geneva, Switzerland
S. A. Wotton />Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
K. Wyllie />European Organization for Nuclear Research (CERN), Geneva, Switzerland
Y. Xie />School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
F. Xing />Department of Physics, University of Oxford, Oxford, United Kingdom
Z. Xing />Syracuse University, Syracuse, NY United States
Z. Yang />Center for High Energy Physics, Tsinghua University, Beijing, China
R. Young />School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
O. Yushchenko />Institute for High Energy Physics (IHEP), Protvino, Russia
M. Zangoli />Sezione INFN di Bologna, Bologna, Italy
M. Zavertyaev />Max-Planck-Institut für Kernphysik (MPIK), Heidelberg, Germany
F. Zhang />Center for High Energy Physics, Tsinghua University, Beijing, China
L. Zhang />Syracuse University, Syracuse, NY United States
W. C. Zhang />School of Physics, University College Dublin, Dublin, Ireland
Y. Zhang />Center for High Energy Physics, Tsinghua University, Beijing, China
A. Zhelezov />Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
L. Zhong />Center for High Energy Physics, Tsinghua University, Beijing, China
A. Zvyagin />European Organization for Nuclear Research (CERN), Geneva, Switzerland

Collapse

Differential branching fraction and angular analysis of the decay B0 → K*0 μ+ μ-

The angular distributions and the partial branching fraction of the decay B0 → K*0 μ+ μ- are studied by using an integrated luminosity of 0.37  fb(-1) of data collected with the LHCb detector. The forward-backward asymmetry of the muons, A(FB), the fraction of longitudinal polarization, F(L), and the partial branching fraction dB/dq2 are determined as a function of the dimuon invariant mass. The measurements are in good agreement with the standard model predictions and are the most precise to date. In the dimuon invariant mass squared range 1.00-6.00  GeV2/c4, the results are A(FB)=-0.06(-0.14)(+0.13)±0.04, F(L)=0.55±0.10±0.03, and dB/dq2=(0.42±0.06±0.03)×10(-7)  c4/GeV2. In each case, the first error is statistical and the second systematic.

First observation of the decays B(0) → D(+)K(-)π(+)π(-) and B(-) → D(0)K(-)π(+)π(-)

First observations of the Cabibbo-suppressed decays B(0) → D(+)K(-)π(+)π(-) and B(-) → D(0)K(-)π(+)π(-) are reported using 35 pb(-1) of data collected with the LHCb detector. Their branching fractions are measured with respect to the corresponding Cabibbo-favored decays, from which we obtain B(B(0) → D(+)K(-)π(+)π(-))/B(B(0) → D(+)π(-)π(+)π(-))=(5.9±1.1±0.5)×10(-2) and B(B(-) → D(0)K(-)π(+)π(-))/B(B(-) → D(0)π(-)π(+)π(-))=(9.4±1.3±0.9)×10(-2), where the uncertainties are statistical and systematic, respectively. The B(-) → D(0)K(-)π(+)π(-) decay is particularly interesting, as it can be used in a similar way to B(-) → D(0)K(-) to measure the Cabibbo-Kobayashi-Maskawa phase γ.

Observation of B(s)(0) → J/ψf(2)'(1525) in J/ψK+ K- final states

The decay B(s)(0) → J/ψK+ K- is investigated using 0.16  fb(-1) of data collected with the LHCb detector using 7 TeV pp collisions. Although the J/ψϕ channel is well known, final states at higher K+ K- masses have not previously been studied. In the K+ K- mass spectrum we observe a significant signal in the f(2)'(1525) region as well as a nonresonant component. After subtracting the nonresonant component, we find B(B(s)(0) → J/ψf(2)'(1525))/B(B(s)(0) → J/ψϕ) = (26.4 ± 2.7 ± 2.4)%.